Sulpiride in combination with fluvoxamine increases in vivo dopamine release selectively in rat prefrontal cortex

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
Yukio AgoToshio Matsuda

Abstract

Coadministration of atypical antipsychotics and selective serotonin reuptake inhibitors (SSRIs) enhances the release of monoamines such as dopamine (DA), norepinephrine (NE), and serotonin (5-HT) in the prefrontal cortex. To clarify the role of DA-D2/3 receptors in the combination effect, we examined the effects of coadministration of the selective DA-D2/3 antagonist sulpiride and the SSRI fluvoxamine on amine neurotransmitter release in rat prefrontal cortex. Sulpiride (10 mg/kg, i.p.) and fluvoxamine (10 mg/kg, i.p.) alone did not affect extracellular DA levels, while their coadministration caused a significant increase in DA levels. Sulpiride alone did not affect extracellular levels of 5-HT and NE in the prefrontal cortex, while fluvoxamine alone caused a marked increase in 5-HT levels and a slight increase in NE levels. Sulpiride did not affect the fluvoxamine-induced increases in extracellular levels of 5-HT and NE. The DA-D2/3 antagonist haloperidol (0.1 mg/kg) in combination with fluvoxamine also caused a selective increase in extracellular DA levels in the cortex. Coadministration of sulpiride and fluvoxamine did not affect extracellular DA levels in the striatum. Combination of systemic sulpiride and local fluvoxamine...Continue Reading

References

Jan 1, 1990·Clinical Neuropharmacology·G SerraG L Gessa
Jan 1, 1986·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·C RobbaG G Nussdorfer
Jan 1, 1984·Acta Psychiatrica Scandinavica. Supplementum·O Benkert, F Holsboer
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
Feb 24, 1998·Journal of Clinical Psychopharmacology·M O'Connor, H Silver
Apr 30, 1999·The Journal of Clinical Psychiatry·R B Ostroff, J C Nelson
Aug 16, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·W ZhangF P Bymaster
Jan 4, 2001·The American Journal of Psychiatry·R C SheltonH Y Meltzer
Feb 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·C Barbui, M Hotopf
Apr 3, 2001·Annual Review of Neuroscience·E K Miller, J D Cohen

❮ Previous
Next ❯

Citations

Dec 27, 2008·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Henry SilverMoussa Youdim
Apr 18, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Mei HuangHerbert Y Meltzer
Jun 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gareth O MintonSarah E Gartside
Dec 17, 2009·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yukio AgoToshio Matsuda
Dec 30, 2015·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Matthijs G P FeenstraDamiaan Denys
Oct 16, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jing ZuoXiao-Hong Lu
Mar 27, 2007·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Pia WeikopJan Kehr
Jun 19, 2010·CNS Neuroscience & Therapeutics·Giuseppe Di GiovanniVincenzo Di Matteo
Mar 26, 2016·Progress in Neurobiology·Philippe De Deurwaerdère, Giuseppe Di Giovanni
Dec 3, 2005·European Journal of Pharmacology·Shigeo NakamuraToshio Matsuda
May 2, 2015·Behavioural Pharmacology·Shigeru HasebeToshio Matsuda
Sep 6, 2005·European Journal of Pharmacology·Yukio AgoToshio Matsuda
Jul 10, 2013·European Journal of Pharmacology·Andrea de BartolomeisCarmine Tomasetti
May 7, 2016·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Toshio Matsuda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.